PAC-1 combination therapy for Uveal Melanoma

Dr. Hergenrother from the University of Illinois at Urbana-Champaign has developed a new synergistic combination therapy using the small molecule PAC-1 and kinase inhibitors for treatment of uveal melanoma. There are no current targeted therapies against this type of cancer, making this combination treatment a promising one.